Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
20 October 2022 - 10:00PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that it will report third quarter 2022
financial results on Tuesday, November 8, 2022 before the market
opens. Axogen management will host an investment-community
conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the November 8, 2022
conference call by phone may do so by dialing toll free at (877)
407-0993 or use the direct dial-in number at (201) 689-8795. Those
interested in listening to the conference call live via the
Internet may do so by visiting the Investors page of the company's
website at www.axogeninc.com and
clicking on the webcast link.
Following the conference call, a replay will be available in the
Investors section of the company's website at
www.axogeninc.com.
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral nerve, or
the inability to properly reconnect peripheral nerves, can result
in the loss of muscle or organ function, the loss of sensory
feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa extracellular matrix (ECM)
coaptation aid for tensionless repair of severed peripheral nerves;
Axoguard Nerve Protector®, a porcine submucosa ECM product used to
wrap and protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, Germany, the United Kingdom, Spain,
South Korea, and several other countries.
Contact:Axogen, Inc.Ed Joyce, Director,
Investor Relationsejoyce@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2023 to Mar 2024